Viking Therapeutics (LTS:0VQA) ROCE % : -21.23% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Viking Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Viking Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2024 was -21.23%.

Viking Therapeutics ROCE % Historical Data

The historical data trend for Viking Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viking Therapeutics ROCE % Chart

Viking Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-11.36

-16.35

-24.96

-40.38

-40.66

Viking Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-58.30	-36.35	-28.83	-32.60	-21.23

Viking Therapeutics ROCE % Calculation

Viking Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-100.827	/	( ( (168.529 - 21.947)	+	(368.49 - 19.135) )	/ 2 )
	=	-100.827	/	( (146.582	+	349.355)	/ 2 )
	=	-100.827	/	247.9685
	=	-40.66 %

Viking Therapeutics's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-136.292	/	( ( (368.49 - 19.135)	+	(967.518 - 32.774) )	/ 2 )
	=	-136.292	/	( ( 349.355	+	934.744 )	/ 2 )
	=	-136.292	/	642.0495
	=	-21.23 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Viking Therapeutics (LTS:0VQA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Viking Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Viking Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Viking Therapeutics (LTS:0VQA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viking Therapeutics Inc (LTS:0VQA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

VKTX:USA 1VT:Germany

Address

9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, USA, 92121

Website

https://www.vikingtherapeutics.com

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Viking Therapeutics (LTS:0VQA) Headlines

No Headlines